[Federal Register Volume 67, Number 166 (Tuesday, August 27, 2002)]
[Notices]
[Page 55024]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-21734]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Blood Products Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on September 12, 2002, from 
8 a.m. to 5:30 p.m.
    Location: Hilton Silver Spring Hotel, Maryland Ballroom, 8727 
Colesville Rd., Silver Spring, MD 20910.
    Contact Person: Linda A. Smallwood, Center for Biologics Evaluation 
and Research (HFM-302), Food and Drug Administration, 1401 Rockville 
Pike, Rockville, MD 20852, 301-827-3514, or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), code 19516. Please call the Information Line for up-to-date 
information on this meeting.
    Agenda: On September 12, 2002, the following committee updates are 
tentatively scheduled: (1) Consideration of the Clinical Laboratory 
Improvement Act (CLIA) waivers for rapid human immunodeficiency virus 
(HIV) tests; (2) implementation of HIV, type 1/hepatitis C virus 
nucleic acid testing algorithm; (3) summary of Public Health Service 
Advisory Committee on Blood Safety and Availability meeting held on 
September 5, 2002; (4) summary of the workshop on pathogen inactivation 
held on August 7 and 8, 2002; and (5) blood establishment registration-
-electronic submissions. In the morning, the committee will hear 
discussion and provide recommendations on the topic of self-
administration of the uniform donor history questionnaire: first time 
donors. In the afternoon, the committee will hear an informational 
presentation on testing for Chagas disease, and a presentation on 
window period for HIV cases and current estimates of residual risk.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by August 30, 
2002. Oral presentations from the public will be scheduled between 
approximately 11 a.m. and 11:30 a.m., and 3:45 p.m. and 4:30 p.m. Time 
allotted for each presentation may be limited. Those desiring to make 
formal oral presentations should notify the contact person before 
August 30, 2002, and submit a brief statement of the general nature of 
the evidence or arguments they wish to present, the names and addresses 
of proposed participants, and an indication of the approximate time 
requested to make their presentation.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Linda A. Smallwood 
or Pearline K. Muckelvene at 301-827-1281 at least 7 days in advance of 
the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: August 20, 2002.
Linda Arey Skladany,
Senior Associate Commissioner for External Relations.
[FR Doc. 02-21734 Filed 8-26-02; 8:45 am]
BILLING CODE 4160-01-S